While born and raised in Calgary, Renée practiced law in Sydney, Australia before returning to her hometown to resume her Canadian legal practice bringing with her a wealth of knowledge and experience gained overseas. Some content on this site is not intended for people outside the United States. please contact us at [email protected] or scan the QR code below. This, along with our other partnerships and internal programs, reflects Gilead’s commitment to continuing innovation to discover a cure for HIV and bring about an end to the HIV epidemic.”, “We are excited to be partnering with Gilead, a company that has decades long experience improving care for people living with HIV, to advance a novel immunotherapy using our proprietary platform for the treatment of HIV infection,” said Andrew Allen, MD, PhD, Co-Founder, President and Chief Executive Officer of Gritstone. Gritstone undertakes no obligation to update or revise any forward-looking statements. Jacquie Ross, Investors On the heels of our recent COVID-19 program initiation in partnership with the NIH, this program adds to our growing infectious disease pipeline supported by collaborations with leading biopharma and renowned institutions.”, “Delivery of viral antigens in potent vaccine vectors to elicit a strong immune response is a cornerstone of successful infectious disease vaccines,” said Karin Jooss, PhD, Executive Vice President of Research and Chief Scientific Officer of Gritstone. +1 760 945 7701, Phone: +1 909 394 4000 Investor Contact. +1 650 574 3000. Floor 31, Century Link Tower 1, No. Press Releases; #Breadcrumb Separator# Gilead Sciences Statement on the Company’s Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV) For more information on Gilead Sciences. The company also has a bispecific antibody (BiSAb) program for solid tumors in lead optimization. For more information, please visit gritstoneoncology.com. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. February 16, 2021. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com. Gilead Jacquie Ross, Investors +1 (408) 656-8793 Arran Attridge, Media +1 (650) 425-8975 Galapagos Elizabeth Goodwin, Investors +1 781 460 1784 Sofie Van Gijsel, Investors +32 485 19 14 15 ir@glpg.com . This press release contains forward-looking statements, including, but not limited to, statements related to the potential of Gritstone’s therapeutic programs; the advancements in the Company’s ongoing clinical trials; the timing of data announcements related to ongoing clinical trials and the initiation of future clinical trials. 1-800-445-3235) Map and Directions. Contacts. Within its infectious disease pipeline, Gritstone is advancing CORAL, a COVID-19 program to develop a second-generation vaccine with support from departments within the National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation and a license agreement with La Jolla Institute for Immunology. We guarantee 100% results in committed time. January 12, 2021. Contacts. Investor Contact. The reader is cautioned not to rely on these forward-looking statements. View the full release here: https://www.businesswire.com/news/home/20210201005208/en/. For more information on Gilead Sciences. For the latest updates on our ongoing response to COVID-19, please, Clinical Trials Transparency & Data Sharing Policy, Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services, Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD. please contact us at [email protected] or scan the QR code below. Gilead and Gritstone will develop an HIV-specific therapeutic vaccine using Gritstone’s proprietary prime-boost vaccine platform, comprised of self-amplifying mRNA (SAM) and adenoviral vectors, with antigens developed by Gilead. Press Releases; #Breadcrumb Separator# Gilead Sciences Statement on Data From Remdesivir Study in Patients With Severe COVID-19 in China For more information on Gilead Sciences. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements. Press Release Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination ... Media +353 (87) 382-6777 VIR CONTACTS: Neera Ravindran, M.D., … Alexandra Santos, Investors We are delighted to now advance our partnership and product candidates for the treatment of patients with HIV infection.”. 1-800-445-3235. Gilead Contacts: Douglas Maffei, PhD, Investors (650) 522-2739 Marni Kottle, Media (650) 522-5388 Arcus Contact: Katherine Bock (510) 694-6231 Get your website ranked in search engine in a very short time. For the latest updates on our ongoing response to COVID-19, please click here. +1 650 574 3000, 1-800-GILEAD-5 (1-800-445-32351-800-445-3235), Phone: +1 760 945 7701 Contacts. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. Gilead Contacts: Jacquie Ross, Investors (650) 425-8408 Mark Snyder, Media (650) 446-6957 Gritstone Contacts: Alexandra Santos, Investors (510) 871-6161 Dan Budwick, Media (973) 271-6085 Source: Gilead Sciences, Inc. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, as filed with the U.S. Securities and Exchange Commission. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead Sciences to Release Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 4, 2021. Gilead Digital. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. View source version on businesswire.com: This press release features multimedia. It would seem that Gilead originally began as various religious extremist groups that believed that America needed to be 'saved' from sin and corruption. Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. to follow the company on WeChat Marni Kottle, Media (650) 522-5388 “Our preclinical work at Gritstone developing our powerful prime-boost vaccine technology utilized simian immunodeficiency virus (SIV) derived antigens as model antigens, which are very similar to HIV-1. Contacts. The Republic of Gilead, sometimes colloquially referred to simply as Gilead, is the authoritarian, theocratic regime that takes over the United States of America in the novel of The Handmaid's Tale. “It is well-established that CD8+ T cells are critical for the elimination of virally infected cells, and we have built a highly differentiated vaccine platform that has been shown to generate large numbers of antigen-specific T cells, including CD8+ T cells, even in advanced and immunocompromised cancer patients. Contacts. (650) 425-8408, Gritstone Contacts: Gilead Sciences to Present at Upcoming Investor Conferences. Phone: +86 21 3893 4588. Institutional Investors, Financial Analysts or Retail Investors, please contact: Gilead Investor Relations. Phone: 1-800-GILEAD-5 (1-800-445-3235) 1-800-GILEAD-5 (1-800-445-3235) Email: public_affairs@gilead.com +1 206 728 5090, Phone:+1 650 574 3000 (510) 871-6161. 888-983-4668, Phone: 1-800-445-3235 Option #2 for product quality complaints, To request a copy of Gilead’s current US commercial return goods policy, please email returns@gilead.com. We jointly performed further experiments that generated additional compelling data, which was also complemented by our exciting clinical data with neoantigens in cancer patients. Phone: (650) 574-3000. For more information, contact us. Vinyl is our format of choice, although sometimes we will release CDs and tapes. Members of the media can reach our press office at: (202) 572-8968 or email press@hrc.org. Press Releases. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. Press Releases; #Breadcrumb Separator# Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19 For more information on Gilead Sciences. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. Some content on this site is not intended for people outside the United States. +1 909 394 4000, Phone: +1 206 728 5090 Gritstone’s vaccine technology has the potential to educate the immune system to specifically recognize and destroy HIV-infected cells by leveraging SAM and adenoviral vectors. Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research. Fax: (650) 578-9264. © 2020 Gilead Sciences, Inc. All rights reserved. January 21, 2021. 1198 Century Avenue, Pudong New Area, Shanghai 200122. Gilead Sciences and Wake Forest University School of Divinity Partner to Address HIV Epidemic … Fax: (650) 522-5853. “While HIV treatment has advanced dramatically over the past three decades, people living with HIV still face a lifetime of therapy,” said Diana Brainard, MD, Senior Vice President, Virology Therapeutic Area, Gilead Sciences. Renée is an experienced business lawyer whose practice focuses on corporate law, mergers and acquisitions and securities law. © 2020 Gilead Sciences, Inc. All rights reserved. 50 were here. Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP®, Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines, https://www.businesswire.com/news/home/20210201005208/en/. This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the ability of the parties to meet potential milestones in the estimated timelines or at all and the risk that the parties may not realize the expected benefits of this collaboration. 1-800-GILEAD-5 (. For the latest updates on our ongoing response to COVID-19, please click here. Gilead House is a transitional home for single mothers in need located in Marin County, California. Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP®, Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines. please contact us at [email protected] or scan the QR code below. +1 650 574 3000, Phone: +1 (650) 574 3000 Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MYR GmbH for up to approximately €1.45 billion in aggregate cash consideration. Gilead Contacts: Douglas Maffei, PhD, Investors (650) 522-2739 Marni Kottle, Media (650) 522-5388 Tizona Contacts: Shari Annes, Investors (650) 888-0902 Janet Graesser, Media (917) 685-8799 Source: Gilead Sciences, Inc. Gilead Contacts: Jacquie Ross, Investors (650) 425-8408 Mark Snyder, Media (650) 446-6957 Gritstone Contacts: Alexandra Santos, Investors … Gilead Contact: Chris Ridley, Media (650) 235-2220 HRC Contact: Elizabeth Bibi, Media (914) 874-6865 Contacts Gilead Contact: Chris Ridley, Media (650) 235-2220 HRC Contact… The resulting strong, durable and broad anti-SIV CD8+ T cell responses and T cell memory data captured the attention of Gilead’s virology team. FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 23, 2020-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire Immunomedics, Inc. (Nasdaq: IMMU) for approximately $21 billion in the aggregate. 168 likes. For the latest updates on our ongoing response to COVID-19, please, Clinical Trials Transparency & Data Sharing Policy, Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services, Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD. 888-983-4668 Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGE™, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patient’s immune system to specifically attack and destroy disease-causing cells. For PR-related inquiries, please contact Shannon at Perfect World PR: Inaperfectworldproductions@gmail.com Gilead Media is a record label based out of Wisconsin that specializes in metal, hardcore, noise rock, and experimental music. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Gritstone’s most recent Quarterly Report on Form 10-Q filed on November 5, 2020 and any current and periodic reports filed with the Securities and Exchange Commission. January 19, 2021. Carmen Vroonen, Media +32 473 824 874 Anna Gibbins, Media +44 (0) 7717 801900 communications@glpg.com. Under the terms of the agreement, Gilead will make a $60 million payment at closing, consisting of a $30 million upfront cash payment and a $30 million equity investment at a premium. Gritstone is also eligible to receive up to an additional $725 million if the option is exercised and if certain clinical, regulatory and commercial milestones are achieved, as well as mid single-digit to low double-digit tiered royalties on net sales upon commercialization. please contact us at [email protected] or scan the QR code below. “We are very pleased to reach today’s milestone and to welcome the talented Immunomedics team to the Gilead family. https://www.businesswire.com/news/home/20210201005208/en/, Gilead Contacts: to follow the company on WeChat. Gilead Jacquie Ross, Investors +1 (408) 656-8793 Arran Attridge, Media +1 (650) 425-8975 Galapagos Elizabeth Goodwin, Investors +1 781 460 1784 Phone: +1 650 574 3000. Such forward-looking statements involve substantial risks and uncertainties that could cause Gritstone’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. If you require medical information of Gilead China products, or report an adverse event of these products, or report a product technical quality complaint, Jacquie Ross, Investors (408) 656-8793. Phone: +1 650 574 3000 Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences. +1-866-MEDI-GSI (1-866-633-4474), For Kite Medical Information, Clinical Trial Inquiries, Adverse, Reactions & Product Complaints contact: (844) 454-KITE(844) 454-KITE, To request specific product information, report an adverse event or product complaint, contact Trodelvy Medical Information: Individual civil liberties as formerly granted by the suspended U.S. Constitution have been replaced by a system of duties and privileges implemented in a hierarchy of social classes, with every former U.S. citizen being assigned to a particular class and expected (and/or forced) to fulfill certain roles (seeSocie… Locust Walk served as transaction advisor to Gritstone. Jacquie Ross, Investors (650) 425-8408. SOURCE: Gilead Sciences, Inc. Gilead Contacts: Jacquie Ross, Investors (650) 425-8408 Mark Snyder, Media (650) 446-6957 Gritstone Contacts: Alexandra Santos, … FOSTER CITY, Calif. & EMERYVILLE, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that the companies have entered into a collaboration, option and license agreement to research and develop a vaccine-based immunotherapy as part of Gilead’s efforts to find a curative treatment for human immunodeficiency virus (HIV) infection. Brian Plummer, Media (202) 309-5207 The label was founded in 2005. +1 (650) 574 30006, Executive Vice President, General Counsel and Chief Compliance Officer, Internet Request: Medical Information Request Form, Phone: +1-866-MEDI-GSI (1-866-633-4474) “Curing HIV remains the ultimate aspiration for Gilead’s HIV research and development efforts. The company strives to transform and simplify care for people with life-threatening illnesses around the world. To make a general inquiry, please visit our contact page. Leading SEO, Digital Marketing, PPC services provider in Bangalore. The company’s lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an “off the shelf” shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including Gritstone’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Gritstone’s ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. Gilead will be responsible for conducting a Phase 1 study for the HIV-specific therapeutic vaccine and holds an exclusive option under the collaboration to obtain an exclusive license to develop and commercialize the HIV-specific therapeutic vaccine beyond Phase 1. February 18, 2021. Source: Gilead Sciences, Inc.